

**Supplementary Table 5. Subgroup analyses of all-cause mortality, myocardial infarction, and stroke according to variability of various metabolic components**

eGFR (mL/min/1.73 m <sup>2</sup> )	Variability (VIM)	Mortality						Myocardial infarction						Stroke							
		No. of subjects	No. of events	Incidence rate <sup>a</sup>	Age-sex adjusted model, aHR (95% CI)	p for interaction	Multivariable model, aHR (95% CI)	p for interaction	No. of events	Incidence rate <sup>a</sup>	Age-sex adjusted model, aHR (95% CI)	p for interaction	Multivariable model, aHR (95% CI)	p for interaction	No. of events	Incidence rate <sup>a</sup>	Age-sex adjusted model, aHR (95% CI)	p for interaction	Multivariable model, aHR (95% CI)	p for interaction	
Weight	ESKD	Q1 (low)	3,495	209	10.19	1 (Reference)	<0.001	1 (Reference)	<0.001	83	4.07	1 (Reference)	0.03	1 (Reference)	0.05	84	4.13	1 (Reference)	0.19	1 (Reference)	0.31
		Q2	3,523	237	11.44	1.14 (0.95-1.37)		1.14 (0.95-1.37)		88	4.28	1.08 (0.80-1.46)		1.06 (0.79-1.43)		80	3.89	0.98 (0.72-1.33)		0.95 (0.70-1.29)	
		Q3	3,714	283	13.07	1.40 (1.17-1.67)		1.32 (1.11-1.58)		96	4.48	1.17 (0.87-1.56)		1.15 (0.86-1.55)		85	3.96	1.01 (0.75-1.37)		0.99 (0.73-1.34)	
		Q4 (high)	4,595	582	22.45	2.19 (1.87-2.57)		1.94 (1.66-2.27)		174	6.81	1.70 (1.31-2.20)		1.63 (1.23-2.12)		172	6.72	1.59 (1.23-2.06)		1.52 (1.17-1.97)	
<30		Q1 (low)	92,361	5,111	9.41	1 (Reference)		1 (Reference)		2,246	4.17	1 (Reference)		1 (Reference)		2,820	5.26	1 (Reference)		1 (Reference)	
		Q2	86,722	5,284	10.35	1.14 (1.09-1.18)		1.10 (1.06-1.14)		2,165	4.28	1.05 (0.99-1.11)		1.05 (0.99-1.11)		2,666	5.29	1.03 (0.97-1.08)		1.02 (0.97-1.08)	
		Q3	86,848	6,378	12.56	1.33 (1.28-1.38)		1.26 (1.21-1.31)		2,322	4.62	1.11 (1.05-1.18)		1.10 (1.04-1.16)		2,991	5.97	1.12 (1.06-1.18)		1.10 (1.05-1.16)	
		Q4 (high)	96,132	11,455	20.90	1.93 (1.87-2.00)		1.71 (1.65-1.77)		3,208	5.92	1.31 (1.25-1.39)		1.28 (1.21-1.35)		4,156	7.72	1.26 (1.20-1.33)		1.22 (1.16-1.28)	
≥30, <60		Q1 (low)	1,318,624	26,117	3.30	1 (Reference)		1 (Reference)		14,877	1.89	1 (Reference)		1 (Reference)		16,284	2.07	1 (Reference)		1 (Reference)	
		Q2	1,291,250	26,269	3.37	1.09 (1.07-1.11)		1.06 (1.04-1.08)		14,333	1.85	1.03 (1.00-1.05)		1.03 (1.00-1.05)		15,689	2.01	1.03 (1.00-1.05)		1.02 (1.00-1.05)	
		Q3	1,255,125	29,512	3.91	1.27 (1.25-1.29)		1.21 (1.19-1.23)		14,317	1.91	1.07 (1.05-1.10)		1.06 (1.04-1.09)		16,141	2.15	1.10 (1.08-1.13)		1.09 (1.07-1.11)	
		Q4 (high)	1,186,055	41,120	5.83	1.74 (1.71-1.77)		1.57 (1.54-1.59)		15,412	2.20	1.22 (1.19-1.24)		1.19 (1.17-1.22)		17,982	2.57	1.23 (1.20-1.25)		1.20 (1.17-1.23)	
≥60		Q1 (low)	1,076,248	14,596	2.26	1 (Reference)		1 (Reference)		8,929	1.38	1 (Reference)		1 (Reference)		8,786	1.36	1 (Reference)		1 (Reference)	
		Q2	1,115,565	15,386	2.28	1.10 (1.07-1.12)		1.07 (1.04-1.09)		9,099	1.35	1.03 (1.00-1.06)		1.03 (1.00-1.06)		8,863	1.32	1.04 (1.01-1.07)		1.04 (1.01-1.07)	
		Q3	1,145,776	17,139	2.48	1.24 (1.21-1.27)		1.19 (1.16-1.21)		9,531	1.38	1.10 (1.07-1.13)		1.09 (1.06-1.12)		9,191	1.33	1.09 (1.06-1.13)		1.08 (1.05-1.12)	
		Q4 (high)	1,205,529	23,853	3.31	1.70 (1.67-1.74)		1.56 (1.53-1.59)		10,260	1.43	1.22 (1.19-1.26)		1.20 (1.16-1.23)		10,292	1.43	1.23 (1.19-1.26)		1.21 (1.17-1.24)	
Waist circumference	ESKD	Q1 (low)	3,724	299	13.81	1 (Reference)	<0.001	1 (Reference)	0.02	99	4.62	1 (Reference)	0.47	1 (Reference)	0.60	92	4.29	1 (Reference)	0.87	1 (Reference)	0.91
		Q2	3,525	288	14.05	1.09 (0.92-1.28)		1.05 (0.90-1.24)		101	4.98	1.12 (0.85-1.48)		1.12 (0.85-1.48)		87	4.28	1.04 (0.78-1.40)		1.04 (0.77-1.39)	
		Q3	3,692	292	13.57	1.02 (0.87-1.20)		0.99 (0.84-1.16)		109	5.11	1.14 (0.87-1.50)		1.15 (0.88-1.51)		103	4.83	1.14 (0.86-1.51)		1.14 (0.86-1.51)	
		Q4 (high)	4,386	432	17.17	1.33 (1.15-1.54)		1.24 (1.07-1.44)		132	5.31	1.21 (0.93-1.57)		1.21 (0.93-1.57)		139	5.59	1.31 (1.01-1.71)		1.31 (1.00-1.70)	
<30		Q1 (low)	90,720	6,449	12.19	1 (Reference)		1 (Reference)		2,433	4.65	1 (Reference)		1 (Reference)		3,044	5.84	1 (Reference)		1 (Reference)	
		Q2	85,745	6,146	12.25	1.06 (1.02-1.09)		1.04 (1.01-1.08)		2,278	4.58	1.01 (0.96-1.07)		1.01 (0.96-1.07)		2,892	5.84	1.03 (0.98-1.09)		1.03 (1.00-1.70)	
		Q3	88,521	6,604	12.77	1.11 (1.08-1.15)		1.08 (1.04-1.12)		2,404	4.69	1.04 (0.98-1.07)		1.04 (0.98-1.10)		3,008	5.90	1.03 (0.98-1.08)		1.03 (0.98-1.08)	
		Q4 (high)	97,077	9,029	16.06	1.36 (1.31-1.40)		1.27 (1.23-1.32)		2,826	5.08	1.09 (1.04-1.16)		1.10 (1.04-1.16)		3,689	6.67	1.09 (1.04-1.15)		1.09 (1.04-1.15)	
≥30, <60		Q1 (low)	1,300,164	29,590	3.80	1 (Reference)		1 (Reference)		15,310	1.97	1 (Reference)		1 (Reference)		16,764	2.16	1 (Reference)		1 (Reference)	
		Q2	1,286,147	28,733	3.71	1.05 (1.03-1.07)		1.03 (1.02-1.05)		14,502	1.88	0.99 (0.97-1.02)		1.00 (0.97-1.02)		16,016	2.08	1.02 (0.99-1.04)		1.02 (0.99-1.04)	
		Q3	1,257,312	29,591	3.92	1.11 (1.09-1.13)		1.08 (1.06-1.10)		14,277	1.90	1.01 (0.98-1.03)		1.01 (0.99-1.03)		16,182	2.15	1.04 (1.01-1.06)		1.04 (1.02-1.06)	
		Q4 (high)	1,207,431	35,104	4.88	1.32 (1.30-1.34)		1.25 (1.23-1.27)		14,850	2.07	1.08 (1.06-1.10)		1.09 (1.06-1.11)		17,034	2.38	1.07 (1.05-1.10)		1.08 (1.05-1.10)	
≥60		Q1 (low)	1,098,867	16,942	2.57	1 (Reference)		1 (Reference)		9,558	1.45	1 (Reference)		1 (Reference)		9,219	1.40	1 (Reference)		1 (Reference)	
		Q2	1,117,790	16,779	2.48	1.04 (1.01-1.06)		1.02 (1.00-1.05)		9,151	1.36	0.97 (0.95-1.00)		0.97 (0.95-1.00)		9,045	1.34	1.01 (0.98-1.04)		1.01 (0.99-1.04)	
		Q3	1,142,606	17,511	2.54	1.10 (1.08-1.12)		1.08 (1.06-1.10)		9,503	1.38	1.02 (0.99-1.05)		1.03 (1.00-1.06)		9,186	1.34	1.03 (1.00-1.06)		1.04 (1.01-1.07)	
		Q4 (high)	1,183,855	19,742	2.78	1.25 (1.22-1.27)		1.20 (1.18-1.22)		9,607	1.36	1.05 (1.02-1.08)		1.07 (1.04-1.10)		9,682	1.37	1.06 (1.03-1.09)		1.08 (1.05-1.11)	

(Continued to the next page)

Supplementary Table 5. Continued

eGFR (mL/min/1.73 m <sup>2</sup> )	Variability (VIM)	Mortality				Myocardial infarction				Stroke							
		No. of subjects	No. of events	Age-sex adjusted incidence rate <sup>a</sup> (95% CI)	p for interaction	Multivariable model, aHR (95% CI)	p for interaction	No. of events	Age-sex adjusted incidence rate <sup>a</sup> (95% CI)	p for interaction	Multivariable model, aHR (95% CI)	p for interaction	No. of events	Age-sex adjusted incidence rate <sup>a</sup> (95% CI)	p for interaction	Multivariable model, aHR (95% CI)	p for interaction
DBP	ESKD	Q1 (low)	3,547	250	12.13	1 (Reference)	<0.001	96	4.71	1 (Reference)	0.24	81	3.96	1 (Reference)	0.74	1 (Reference)	0.76
		Q2	3,495	275	13.45	1.09 (0.92-1.30)		86	4.24	0.91 (0.68-1.21)		83	4.09	1.04 (0.77-1.41)		1.03 (0.76-1.39)	
		Q3	3,573	251	11.98	1.03 (0.86-1.22)		107	5.16	1.13 (0.86-1.49)		94	4.53	1.19 (0.88-1.60)		1.14 (0.85-1.53)	
		Q4 (high)	4,712	535	19.96	1.44 (1.24-1.67)		152	5.73	1.14 (0.88-1.47)		163	6.16	1.40 (1.08-1.83)		1.32 (1.01-1.72)	
<30		Q1 (low)	83,714	5,338	10.93	1 (Reference)		2,039	4.21	1 (Reference)		2,611	5.42	1 (Reference)		1 (Reference)	
		Q2	84,202	6,182	12.52	1.11 (1.07-1.15)		2,251	4.60	1.07 (1.01-1.14)		2,814	5.78	1.04 (0.99-1.10)		1.02 (0.97-1.08)	
		Q3	82,994	5,902	12.15	1.12 (1.08-1.16)		2,172	4.51	1.08 (1.02-1.15)		2,707	5.65	1.06 (1.00-1.12)		1.04 (0.99-1.10)	
		Q4 (high)	111,153	10,806	16.84	1.32 (1.28-1.37)		3,479	5.48	1.19 (1.13-1.26)		4,501	7.13	1.16 (1.11-1.22)		1.11 (1.05-1.16)	
≥30, <60		Q1 (low)	1,265,497	27,141	3.59	1 (Reference)		13,922	1.85	1 (Reference)		14,998	2.00	1 (Reference)		1 (Reference)	
		Q2	1,266,088	29,008	3.80	1.06 (1.04-1.08)		14,273	1.88	1.03 (1.00-1.05)		15,778	2.08	1.06 (1.03-1.08)		1.03 (1.01-1.06)	
		Q3	1,253,067	27,615	3.66	1.08 (1.06-1.09)		13,598	1.81	1.02 (0.99-1.04)		14,985	2.00	1.06 (1.03-1.08)		1.03 (1.01-1.06)	
		Q4 (high)	1,266,402	39,254	5.19	1.21 (1.20-1.23)		17,146	2.28	1.12 (1.09-1.14)		20,235	2.69	1.17 (1.15-1.20)		1.11 (1.09-1.13)	
≥60		Q1 (low)	1,139,923	16,108	2.36	1 (Reference)		9,057	1.33	1 (Reference)		8,620	1.27	1 (Reference)		1 (Reference)	
		Q2	1,139,292	16,920	2.45	1.05 (1.03-1.07)		9,092	1.32	1.01 (0.98-1.04)		8,860	1.29	1.04 (1.01-1.07)		1.02 (0.99-1.05)	
		Q3	1,153,285	16,719	2.40	1.08 (1.06-1.10)		9,184	1.32	1.03 (1.01-1.07)		8,605	1.24	1.03 (1.00-1.07)		1.02 (0.99-1.05)	
		Q4 (high)	1,110,618	21,227	3.19	1.17 (1.15-1.20)		10,486	1.58	1.11 (1.08-1.14)		11,047	1.67	1.18 (1.14-1.21)		1.12 (1.09-1.15)	
LDL	ESKD	Q1 (low)	3,124	199	10.69	1 (Reference)	<0.001	88	4.78	1 (Reference)	0.12	83	4.51	1 (Reference)	0.10	1 (Reference)	0.14
		Q2	3,145	215	11.68	1.22 (1.01-1.48)		71	3.89	0.88 (0.65-1.21)		69	3.78	0.92 (0.67-1.26)		0.90 (0.68-1.24)	
		Q3	3,664	295	13.92	1.43 (1.20-1.71)		90	4.29	0.97 (0.72-1.30)		86	4.09	0.98 (0.72-1.32)		0.95 (0.70-1.28)	
		Q4 (high)	5,394	602	19.68	1.85 (1.58-2.18)		192	6.35	1.35 (1.05-1.73)		183	6.05	1.34 (1.03-1.73)		1.22 (0.94-1.58)	
<30		Q1 (low)	84,454	6,221	12.42	1 (Reference)		2,233	4.50	1 (Reference)		2,845	5.76	1 (Reference)		1 (Reference)	
		Q2	76,758	5,252	11.71	1.00 (0.97-1.04)		1,930	4.34	1.01 (0.95-1.06)		2,462	5.57	1.02 (0.97-1.08)		1.01 (0.96-1.06)	
		Q3	83,467	6,216	12.83	1.08 (1.05-1.12)		2,149	4.48	1.03 (0.97-1.10)		2,847	5.96	1.07 (1.02-1.13)		1.04 (0.99-1.09)	
		Q4 (high)	117,384	10,539	15.59	1.22 (1.18-1.26)		3,629	5.43	1.18 (1.12-1.24)		4,479	6.73	1.12 (1.07-1.18)		1.03 (0.98-1.08)	
≥30, <60		Q1 (low)	1,301,736	29,301	3.72	1 (Reference)		14,990	1.91	1 (Reference)		16,752	2.14	1 (Reference)		1 (Reference)	
		Q2	1,271,696	26,086	3.42	1.03 (1.02-1.05)		13,544	1.78	1.01 (0.99-1.03)		14,698	1.93	1.00 (0.98-1.02)		0.99 (0.97-1.01)	
		Q3	1,246,886	28,246	3.79	1.10 (1.09-1.12)		13,691	1.84	1.03 (1.00-1.05)		15,388	2.07	1.04 (1.02-1.06)		1.01 (0.99-1.03)	
		Q4 (high)	1,230,736	39,385	5.38	1.27 (1.25-1.29)		16,714	2.29	1.11 (1.09-1.13)		19,158	2.63	1.10 (1.07-1.12)		1.00 (0.98-1.02)	
≥60		Q1 (low)	1,103,557	15,656	2.34	1 (Reference)		9,192	1.38	1 (Reference)		9,032	1.36	1 (Reference)		1 (Reference)	
		Q2	1,141,320	14,735	2.14	1.04 (1.01-1.06)		8,712	1.27	1.01 (0.98-1.04)		8,339	1.22	1.00 (0.97-1.03)		0.99 (0.97-1.02)	
		Q3	1,158,860	16,480	2.37	1.13 (1.11-1.15)		8,929	1.29	1.02 (0.99-1.05)		8,687	1.25	1.02 (0.99-1.05)		0.99 (0.97-1.02)	
		Q4 (high)	1,139,381	24,103	3.53	1.37 (1.35-1.40)		10,986	1.62	1.13 (1.10-1.16)		11,074	1.63	1.13 (1.10-1.16)		1.02 (0.99-1.05)	

(Continued to the next page)

Supplementary Table 5. Continued

eGFR category (mL/min/1.73 m <sup>2</sup> )	Variability (VIM)	No. of subjects	Mortality				Myocardial infarction				Stroke						
			No. of events	Incidence rate <sup>a</sup>	Age-sex adjusted model, aHR (95% CI)	p for interaction	No. of events	Incidence rate <sup>a</sup>	Age-sex adjusted model, aHR (95% CI)	p for interaction	No. of events	Incidence rate <sup>a</sup>	Age-sex adjusted model, aHR (95% CI)	p for interaction			
HDL	ESKD	Q1 (low)	3,486	11.79	1 (Reference)	<0.001	89	4.34	1 (Reference)	0.24	1 (Reference)	0.23	94	4.58	1 (Reference)	0.22	1 (Reference)
		Q2	3,233	11.32	1.03 (0.86-1.24)		67	3.57	0.88 (0.64-1.20)		0.88 (0.64-1.21)		74	3.95	0.92 (0.68-1.25)		0.92 (0.68-1.25)
		Q3	3,685	11.92	1.06 (0.89-1.26)		95	4.48	1.07 (0.80-1.43)		1.04 (0.78-1.39)		79	3.72	0.84 (0.62-1.14)		0.82 (0.61-1.11)
		Q4 (high)	4,923	21.50	1.59 (1.37-1.84)		190	6.93	1.48 (1.15-1.90)		1.40 (1.09-1.80)		174	6.33	1.23 (0.96-1.58)		1.16 (0.91-1.50)
	<30	Q1 (low)	80,388	11.55	1 (Reference)		1,914	4.03	1 (Reference)		1 (Reference)		2,491	5.27	1 (Reference)		1 (Reference)
		Q2	74,852	11.09	1.02 (0.98-1.06)		1,816	4.19	1.09 (1.02-1.16)		1.09 (1.02-1.16)		2,362	5.47	1.09 (1.03-1.16)		1.09 (1.03-1.15)
		Q3	85,519	12.40	1.08 (1.04-1.12)		2,273	4.62	1.16 (1.09-1.24)		1.14 (1.07-1.21)		2,797	5.71	1.09 (1.03-1.16)		1.07 (1.01-1.13)
		Q4 (high)	121,304	16.77	1.29 (1.25-1.33)		3,938	5.71	1.32 (1.25-1.40)		1.26 (1.19-1.33)		4,983	7.27	1.25 (1.19-1.31)		1.19 (1.14-1.25)
	≥30, <60	Q1 (low)	1,268,891	27.246	3.54 (1 (Reference)		13,251	1.73	1 (Reference)		1 (Reference)		15,058	1.97	1 (Reference)		1 (Reference)
		Q2	1,254,466	24.702	3.28 (1.02 (1.00-1.04)		12,606	1.68	1.04 (1.01-1.06)		1.03 (1.00-1.05)		13,887	1.85	1.02 (1.00-1.05)		1.01 (0.99-1.04)
		Q3	1,257,821	28.462	3.78 (1.07 (1.06-1.09)		14,292	1.91	1.11 (1.09-1.14)		1.09 (1.06-1.12)		15,638	2.09	1.07 (1.05-1.09)		1.05 (1.02-1.07)
		Q4 (high)	1,269,876	42.608	5.65 (1.25 (1.23-1.27)		18,790	2.51	1.25 (1.22-1.28)		1.19 (1.16-1.21)		21,413	2.86	1.19 (1.16-1.21)		1.13 (1.11-1.15)
	≥60	Q1 (low)	1,140,151	15.465	2.24 (1 (Reference)		8,449	1.22	1 (Reference)		1 (Reference)		8,486	1.23	1 (Reference)		1 (Reference)
		Q2	1,160,468	14.336	2.05 (1.01 (0.99-1.03)		8,486	1.22	1.05 (1.02-1.09)		1.04 (1.01-1.07)		8,080	1.16	1.02 (0.99-1.05)		1.01 (0.98-1.04)
		Q3	1,145,575	16.709	2.43 (1.09 (1.07-1.12)		9,354	1.36	1.12 (1.09-1.15)		1.09 (1.06-1.13)		8,869	1.29	1.06 (1.03-1.10)		1.04 (1.01-1.07)
		Q4 (high)	1,096,924	24.464	3.74 (1.31 (1.28-1.33)		11,530	1.77	1.25 (1.22-1.29)		1.19 (1.15-1.22)		11,697	1.79	1.20 (1.17-1.24)		1.15 (1.11-1.18)
TG	ESKD	Q1 (low)	4,245	16.02	1 (Reference)	<0.001	129	5.29	1 (Reference)	0.11	1 (Reference)	0.23	116	4.75	1 (Reference)	0.14	1 (Reference)
		Q2	3,840	32.2	1.04 (0.90-1.21)		99	4.49	0.93 (0.72-1.21)		0.94 (0.72-1.22)		107	4.87	1.15 (0.88-1.50)		1.16 (0.89-1.51)
		Q3	3,706	28.9	1.07 (0.92-1.24)		105	4.95	1.08 (0.84-1.40)		1.09 (0.84-1.41)		100	4.71	1.20 (0.92-1.57)		1.19 (0.91-1.56)
		Q4 (high)	3,536	30.5	1.11 (0.96-1.29)		108	5.33	1.14 (0.88-1.47)		1.18 (0.91-1.52)		98	4.83	1.18 (0.91-1.55)		1.21 (0.93-1.59)
	<30	Q1 (low)	107,912	9.245	1 (Reference)		3,209	5.11	1 (Reference)		1 (Reference)		4,083	6.54	1 (Reference)		1 (Reference)
		Q2	93,394	7.366	1.02 (0.99-1.05)		2,608	4.87	1.01 (0.96-1.07)		1.02 (0.96-1.07)		3,285	6.16	1.01 (0.97-1.06)		1.01 (0.97-1.06)
		Q3	85,892	6.499	1.03 (1.00-1.06)		2,277	4.62	0.99 (0.94-1.05)		1.00 (0.95-1.06)		2,894	5.90	1.01 (0.96-1.06)		1.01 (0.96-1.06)
		Q4 (high)	74,865	5.118	1.09 (0.99-1.02)		1,847	4.26	0.96 (0.91-1.02)		0.99 (0.94-1.05)		2,371	5.49	1.00 (0.95-1.05)		1.02 (0.97-1.08)
	≥30, <60	Q1 (low)	1,317,445	36.287	4.56 (1 (Reference)		17,463	2.21	1 (Reference)		1 (Reference)		19,805	2.51	1 (Reference)		1 (Reference)
		Q2	1,286,437	30.938	4.02 (1.01 (0.99-1.02)		15,038	1.96	0.97 (0.95-1.00)		0.98 (0.96-1.00)		16,715	2.18	0.98 (0.96-1.00)		0.98 (0.96-1.00)
		Q3	1,251,886	28.838	3.85 (1.01 (0.99-1.02)		14,021	1.88	0.96 (0.94-0.98)		0.98 (0.96-1.00)		15,527	2.09	0.96 (0.94-0.98)		0.98 (0.96-1.00)
		Q4 (high)	1,195,286	26.955	3.76 (1.03 (1.01-1.04)		12,417	1.74	0.92 (0.90-0.94)		0.96 (0.94-0.99)		13,949	1.96	0.94 (0.92-0.96)		0.97 (0.95-0.99)
	≥60	Q1 (low)	1,063,280	18.579	2.89 (1 (Reference)		9,974	1.56	1 (Reference)		1 (Reference)		10,062	1.57	1 (Reference)		1 (Reference)
		Q2	1,109,104	17.288	2.59 (1.03 (1.01-1.05)		9,657	1.45	1.02 (0.99-1.05)		1.02 (1.00-1.04)		9,348	1.41	1.01 (0.98-1.03)		1.01 (0.98-1.03)
		Q3	1,151,530	16.951	2.45 (1.03 (1.00-1.05)		9,161	1.33	0.97 (0.94-1.00)		0.99 (0.96-1.02)		8,877	1.29	0.96 (0.93-0.99)		0.97 (0.95-1.00)
		Q4 (high)	1,219,204	18.156	2.48 (1.09 (1.07-1.11)		9,027	1.23	0.94 (0.91-0.96)		0.99 (0.96-1.01)		8,845	1.21	0.94 (0.92-0.97)		0.98 (0.95-1.00)

aHR, adjusted hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; DBP, diastolic blood pressure; ESKD, end-stage kidney disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Q, quartile; TG, triglycerides; VIM, variability independent of the mean.  
<sup>a</sup>The number of high-variability components was calculated by summing the presence of high variability (Q4) in a metabolic parameter from each metabolic syndrome domain (body mass index [BMI], fasting blood glucose, systolic BP, and total cholesterol). <sup>b</sup>Incidence rate (/1,000 person-years). <sup>c</sup>The multivariable model was adjusted for age, sex, low-income status, current smoking, alcohol consumption, regular physical activity, history of diabetes mellitus, hypertension, dyslipidemia, and BMI.